data financed potent tremendous Amanda. of over can meaningful last conjugates on thank development as We EHA in build meetings ensure the with promising progress commercial made patients. our this We our for We Advanced reported and all company pipeline out our ADC objectives. for several across and key us drug medical readouts we targeted ASH. our such and the infrastructure Therapeutics. to Thanks, year antibody joining morning. programs And and and goals you execute team
fourth saw come work the together this quarter, for we Lonca of treatment submission of FDA of much lead acceptance relapsed BLA During DLBCL. we product our hard refractory in received when our the candidate,
I'll our As commercial, across that on ensuring approach prepared and launch planned XXst, well we CMC launch, we May medical in date we our PDUFA preparations a about the share are more support functions. moment. affairs, commercial and are
second our in completed an enrollments our For detail interim lead patients. step We closer pre-treated to addressing Cami more Hodgkin on need this program, the trial from the half first trial, data program Cami, to shortly. in in one Jay us of heavily updated lymphoma potentially we into look year. forward pivotal go our reporting bringing unmet the will
platform Translation Research advancement & programs. in Innovation research-stage Center preclinical further innovation, enable Research and Center or I-HUB the our London. including Central team at research We support London-based in also ADC a are we pipeline portfolio. Drug productive To Therapeutics, invest state-of-the-art we a Conjugate to continuing new Antibody effort, moving to are of The Imperial of College would ADC at and seven our pipeline Hub the this of had research very and research our
of May - candidates a ADCT's and hematologic filing announced global December, preparations. of in more our product we launch the formation XXst, launch to commercialize and ADCT solid with and for tumors four develop BioPharma date out priority and venture, update prepare new in-depth joint build XXXX. Singapore. our footprint, Lonca I now in granted BLA As for Lonca to of and FDA we give the continue review to a and like November, our would In Greater you a for PDUFA accepted Overland target China
systemic submission is safety evaluated lines discussed, of two refractory patients data therapy. as with difficult-to-treat following which patients Lonca our prior as previously in across from of The our DLBCL and LOTIS have we activity based relapsed well relapsed approval. subject broad As manageable significant pivotal on this or trial, efficacy Phase or preparations data We're demonstrates to DLBCL, agent the toxicities X launch more patients, and single X, finalizing Lonca's including a refractory of for population with durability, or disease.
experienced we across with centers have the focused medical and the medical with oncology interactions. We're these field insights gained leading engaging access been thought valuable community team successfully have We leaders, highly country. deployed leaders DLBCL through to the a and very academic and affairs who encouraged has very clinicians
Our is preparations fully making for anticipated onboard launch. sales force final the and
national of have We force and networks experience recruited the deep communicate a oncology local the professionals with strong hematological sales longer seasoned value proposition. effectively experience, to
purely are and guidelines, interactions. from teams to to our local with include, all face-to-face and institutional virtual, engage plans to our launch well ready well Our customer as individual the of hybrid, And engagement respecting approach, ranging positioned as customers customer an preference.
access multichannel We Lonca. office ensure physicians, safe that to key all managers, audiences, payers information administration the support and of ensure the receive nurses, to communications have and and necessary open patients developed
needs other begun DLBCL. MSLs medical Our discussions stakeholders in Account with the have Directors unmet with key appropriate and patients payers regarding and
able line. profile that have line in US we Lonca. and the opportunity estimated met As for to of become teams of address profile care with patients the create an access standard about of our plus EU stakeholders The third XX,XXX billion. differentiated size it a or Lonca's the creates And in MSLs cross-functional to believe questions DLBCL third market have $X been
our Avid, previously and agencies. manufacturers on from CMC all inspected highly for contract been a regulatory DSP, also track are perspective, of by We and example, all have are experienced, Lonza
the ensure our implementing also logistics launch in supply third-party readiness. to We our US
Lonca through full our In of we also lifecycle have potential towards addition to our launch progress realizing development important efforts. preparations, made the
as and Lonca I future. discuss in the greater our of hand well We Feingold, will Jay? Cami earlier and this programs to indications the Jay new fully Chief as Medical now our over developing to detail. are in who move call treatment lines into earlier-stage will Officer,
